New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
10:37 EDTNWBONorthwest Biotherapeutics slides after presentation at cancer conference
Northwest Biotherapeutics (NWBO), a development-stage company focused on immunotherapy products that generate and enhance immune system responses to treat cancer, is trading down sharply after the company presented information about its cancer vaccine DC-Vax. The company's disclosures about the brain cancer study had issues, according to a report by Adam Feuerstein of The Street. WHAT'S NOTABLE: Yesterday, Northwest Biotherapeutics disclosed information about its cancer vaccine DC-Vax and its ongoing phase III brain cancer study during a presentation at the New York Academy of Medicine. Feuerstein's report contended that the information was "amazingly negative" and that CEO Linda Powers "spun the bad news in the opposite direction." The biotech reporter added that Powers would not give specific details about patient enrollment in the study. PRICE ACTION: Northwest Biotherapeutics is trading down 62c, or 7.97%, to $7.16 in morning trading. Reference Link
News For NWBO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
08:57 EDTNWBOLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use